Corner Growth Acquisition Corp. logo
Corner Growth Acquisition Corp. COOL

Quarterly report 2025-Q1
added 07-16-2025

report update icon

Corner Growth Acquisition Corp. Balance Sheet 2011-2026 | COOL

Annual Balance Sheet Corner Growth Acquisition Corp.

2024 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Total Current Liabilities

30.2 K 4.72 M 195 K 162 K - - - - - - - - -

Total Liabilities

297 K 9.35 M 28.7 M 14.2 M - - - - - - - - -

Retained Earnings

-6.06 M -5.78 M -27.6 M - - - - - - - - - -

Total Assets

1.97 M 15.8 M 401 M 403 M - - - - - - - - -

Cash and Cash Equivalents

- 31.5 K 647 K 1.92 M - - - - - - - - -

Book Value

1.67 M 6.44 M 372 M 389 M - - - - - - - - -

Total Shareholders Equity

-297 K -5.78 M -27.6 M -33 M - - - - - - - - -

All numbers in USD currency

Quarterly Balance Sheet Corner Growth Acquisition Corp.

2025-Q1 2024-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Total Liabilities

171 K 429 K 9.91 M 8.58 M - 15.1 M 15.5 M 20.4 M 28.7 M 31 M 39.4 M 34.9 M 35.7 M 35.7 M 35.7 M 35.7 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Retained Earnings

-5.93 M -6.19 M -9.77 M -8.32 M - -14.9 M -15.2 M -19.7 M -27.6 M -29.5 M -5.57 M -722 K -33 M -33 M -1.13 M -1.13 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Assets

1.98 M 3.34 M 4.58 M 12.6 M - 403 M 401 M 401 M 401 M 401 M 402 M 402 M 403 M 403 M 403 M 403 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cash and Cash Equivalents

- - 27.1 K 29.3 K - 86 K 170 K 261 K 647 K 873 K 1.26 M 1.54 M 1.92 M 1.92 M 1.92 M 1.92 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Book Value

1.81 M 2.91 M -5.33 M 4.06 M - 388 M 386 M 380 M 372 M 370 M 363 M 367 M 367 M 367 M 367 M 367 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Shareholders Equity

-171 K -429 K -9.77 M -8.32 M - -14.9 M -15.2 M -19.7 M -27.6 M -29.5 M -37.5 M -32.6 M -33 M -33 M 5 M 5 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Balance Sheet is a fundamental financial report of Corner Growth Acquisition Corp., providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Biotechnology

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Grifols, S.A. Grifols, S.A.
GRFS
$ 8.24 -0.12 % $ 6.83 B spainSpain
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 229.25 0.44 % $ 5 B danmarkDanmark
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
AbbVie AbbVie
ABBV
$ 208.84 -2.86 % $ 369 B usaUSA
AbCellera Biologics AbCellera Biologics
ABCL
$ 3.52 0.28 % $ 1.05 B canadaCanada
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Agenus Agenus
AGEN
$ 3.33 -2.06 % $ 99 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
- 10.36 % $ 9.8 M usaUSA
Adaptive Biotechnologies Corporation Adaptive Biotechnologies Corporation
ADPT
$ 14.81 2.63 % $ 2.25 B usaUSA
Altimmune Altimmune
ALT
$ 3.34 7.05 % $ 294 M usaUSA
BioNTech SE BioNTech SE
BNTX
$ 91.18 1.97 % $ 27.2 B germanyGermany
Amgen Amgen
AMGN
$ 347.94 -1.51 % $ 187 B usaUSA
ANI Pharmaceuticals ANI Pharmaceuticals
ANIP
$ 74.21 -2.3 % $ 1.43 B usaUSA
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings
ARCT
$ 8.03 2.29 % $ 220 M israelIsrael
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Aurinia Pharmaceuticals Aurinia Pharmaceuticals
AUPH
$ 15.61 0.9 % $ 2.1 B canadaCanada
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.41 2.17 % $ 375 M britainBritain
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
Aytu BioScience Aytu BioScience
AYTU
$ 2.68 1.52 % $ 16.8 M usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
AstraZeneca PLC AstraZeneca PLC
AZN
- - $ 96.9 B britainBritain
Burford Capital Limited Burford Capital Limited
BUR
$ 4.14 -2.59 % $ 683 M britainBritain
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
Atea Pharmaceuticals Atea Pharmaceuticals
AVIR
$ 5.76 1.95 % $ 469 M usaUSA
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
BioCryst Pharmaceuticals BioCryst Pharmaceuticals
BCRX
$ 9.02 -3.84 % $ 1.86 B usaUSA
Axcella Health Axcella Health
AXLA
- -16.42 % $ 249 M usaUSA
Axon Enterprise Axon Enterprise
AXON
$ 412.81 -2.54 % $ 31.3 B usaUSA
Alnylam Pharmaceuticals Alnylam Pharmaceuticals
ALNY
$ 318.85 -3.01 % $ 41.8 B usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael